US Government's Vaccine Split Could Create Pharmaceutical Supply Chain Chaos

The US government has announced plans to split the MMR (measles, mumps, and rubella) vaccine into three separate vaccines. This decision raises concerns about the impact on the pharmaceutical supply chain, which is built around the combination vaccine.

Currently, there are two licensed MMR products in the US: Merck's M-M-R II and GSK's PRIORIX. However, individual measles, mumps, and rubella vaccines are not currently available as licensed US products. This means that manufacturers would have to develop or reintroduce commercial products and build the operating infrastructure around them.

Separating the MMR vaccine into three separate products could require building three new supply chains from a licensing base that does not yet exist. This would be a complex task, requiring separate production planning, filling operations, quality testing, labeling, packaging configurations, inventory policies, demand forecasts, contracting, and distribution requirements.

The transition to separate vaccines could take years or even up to a decade, according to experts. The process of developing or modifying biologics manufacturing, validating processes, obtaining approval, scaling production, and establishing commercial distribution can be lengthy and uncertain.